271 related articles for article (PubMed ID: 37176077)
1. The Potential of Cylindromatosis (CYLD) as a Therapeutic Target in Oxidative Stress-Associated Pathologies: A Comprehensive Evaluation.
Huang Z; Tan Y
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176077
[TBL] [Abstract][Full Text] [Related]
2. IκB kinase promotes Nrf2 ubiquitination and degradation by phosphorylating cylindromatosis, aggravating oxidative stress injury in obesity-related nephropathy.
Chen YY; Hong H; Lei YT; Zou J; Yang YY; He LY
Mol Med; 2021 Oct; 27(1):137. PubMed ID: 34711178
[TBL] [Abstract][Full Text] [Related]
3. CYLD destabilizes NoxO1 protein by promoting ubiquitination and regulates prostate cancer progression.
Haq S; Sarodaya N; Karapurkar JK; Suresh B; Jo JK; Singh V; Bae YS; Kim KS; Ramakrishna S
Cancer Lett; 2022 Jan; 525():146-157. PubMed ID: 34742871
[TBL] [Abstract][Full Text] [Related]
4. CYLD induces high oxidative stress and DNA damage through class I HDACs to promote radiosensitivity in nasopharyngeal carcinoma.
Li Y; Yang C; Xie L; Shi F; Tang M; Luo X; Liu N; Hu X; Zhu Y; Bode AM; Gao Q; Zhou J; Fan J; Li X; Cao Y
Cell Death Dis; 2024 Jan; 15(1):95. PubMed ID: 38287022
[TBL] [Abstract][Full Text] [Related]
5. [Research progress of deubiquitinating enzyme CYLD to regulate liver-related diseases].
Yang X; An DJ; Gao CC; Qin HY
Zhonghua Gan Zang Bing Za Zhi; 2019 Jun; 27(6):477-480. PubMed ID: 31357769
[TBL] [Abstract][Full Text] [Related]
6. Potential role of CYLD (Cylindromatosis) as a deubiquitinating enzyme in vascular cells.
Takami Y; Nakagami H; Morishita R; Katsuya T; Hayashi H; Mori M; Koriyama H; Baba Y; Yasuda O; Rakugi H; Ogihara T; Kaneda Y
Am J Pathol; 2008 Mar; 172(3):818-29. PubMed ID: 18245814
[TBL] [Abstract][Full Text] [Related]
7. Oxidative stress-induced lncRNA CYLD-AS1 promotes RPE inflammation via Nrf2/miR-134-5p/NF-κB signaling pathway.
Du H; Huang Z; Zhou X; Kuang X; Long C; Tang H; Zeng J; Huang H; Liu H; Zhu B; Fu L; Hu K; Lin S; Wang H; Zhang Q; Yan J; Shen H
FASEB J; 2022 Oct; 36(10):e22577. PubMed ID: 36165267
[TBL] [Abstract][Full Text] [Related]
8. Spata2L Suppresses TLR4 Signaling by Promoting CYLD-Mediated Deubiquitination of TRAF6 and TAK1.
Zhang Z; Zhang S; Jiang X; Wu D; Du Y; Yang XD
Biochemistry (Mosc); 2022 Sep; 87(9):957-964. PubMed ID: 36180997
[TBL] [Abstract][Full Text] [Related]
9. Catalytic domain mutation in CYLD inactivates its enzyme function by structural perturbation and induces cell migration and proliferation.
Johari T; Maiti TK
Biochim Biophys Acta Gen Subj; 2018 Sep; 1862(9):2081-2089. PubMed ID: 29807073
[TBL] [Abstract][Full Text] [Related]
10. Vinpocetine Suppresses
Komatsu K; Nam DH; Lee JY; Yoneda G; Yan C; Li JD
J Immunol; 2020 Feb; 204(4):933-942. PubMed ID: 31900337
[TBL] [Abstract][Full Text] [Related]
11. Potential role for the tumor suppressor CYLD in brain and notochord development.
Li T; Wang Y; Li D; Zhou J; Zhang B; He X
Thorac Cancer; 2021 Jun; 12(12):1900-1908. PubMed ID: 33982884
[TBL] [Abstract][Full Text] [Related]
12. Pathophysiological significance of cylindromatosis in the vascular endothelium and macrophages for the initiation of age-related atherogenesis.
Imaizumi Y; Takami Y; Yamamoto K; Nagasawa M; Nozato Y; Nozato S; Takeshita H; Wang C; Yokoyama S; Hayashi H; Hongyo K; Akasaka H; Takeya Y; Sugimoto K; Nakagami H; Rakugi H
Biochem Biophys Res Commun; 2019 Jan; 508(4):1168-1174. PubMed ID: 30554661
[TBL] [Abstract][Full Text] [Related]
13. Cylindromatosis Is Required for Survival of a Subset of Melanoma Cells.
La T; Jin L; Liu XY; Song ZH; Farrelly M; Feng YC; Yan XG; Zhang YY; Thorne RF; Zhang XD; Teng L
Oncol Res; 2020 Sep; 28(4):385-398. PubMed ID: 32252875
[TBL] [Abstract][Full Text] [Related]
14. Dishevelled proteins and CYLD reciprocally regulate each other in CML cell lines.
Çalışkan C; Pehlivan M; Yüce Z; Sercan O
Mol Biol Rep; 2017 Oct; 44(5):391-397. PubMed ID: 28840581
[TBL] [Abstract][Full Text] [Related]
15. Reactive oxygen species-dependent down-regulation of tumor suppressor genes PTEN, USP28, DRAM, TIGAR, and CYLD under oxidative stress.
Kim SJ; Jung HJ; Lim CJ
Biochem Genet; 2013 Dec; 51(11-12):901-15. PubMed ID: 23832602
[TBL] [Abstract][Full Text] [Related]
16. Cylindromatosis (CYLD), a Deubiquitinase, Attenuates Inflammatory Signaling Pathways by Activating Toll-Like Receptor 3 in Human Mesangial Cells.
Imaizumi T; Hayakari R; Watanabe S; Aizawa T; Matsumiya T; Yoshida H; Tsuruga K; Kawaguchi S; Tanaka H
Kidney Blood Press Res; 2017; 42(5):942-950. PubMed ID: 29166644
[TBL] [Abstract][Full Text] [Related]
17. Oxidative Stress: A Key Modulator in Neurodegenerative Diseases.
Singh A; Kukreti R; Saso L; Kukreti S
Molecules; 2019 Apr; 24(8):. PubMed ID: 31013638
[TBL] [Abstract][Full Text] [Related]
18. Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell Carcinoma.
Suenaga N; Kuramitsu M; Komure K; Kanemaru A; Takano K; Ozeki K; Nishimura Y; Yoshida R; Nakayama H; Shinriki S; Saito H; Jono H
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31635163
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of miR‑181b inhibits human colon cancer cell proliferation by targeting CYLD and inhibiting the NF‑κB signaling pathway.
Yang X; Sun Y; Zhang Y; Han S
Int J Mol Med; 2020 Nov; 46(5):1755-1764. PubMed ID: 32901872
[TBL] [Abstract][Full Text] [Related]
20. Loss of CYLD promotes cell invasion via ALK5 stabilization in oral squamous cell carcinoma.
Shinriki S; Jono H; Maeshiro M; Nakamura T; Guo J; Li JD; Ueda M; Yoshida R; Shinohara M; Nakayama H; Matsui H; Ando Y
J Pathol; 2018 Mar; 244(3):367-379. PubMed ID: 29235674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
